ArticleParasites & vectors2025
Model development to assess the impact of a preventive treatment with sarolaner and moxidectin on Dirofilaria immitis infection dynamics in dogs.
Article in Parasites & vectors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDirofilaria immitis is a mosquito-transmitted filarial parasite causing heartworm disease in dogs. The parasite may cause a significant disease burden to the dog population in high prevalence areas and is mainly managed through prophylactic treatments.
methodsIn this modelling study, the effect of a prophylactic treatment with moxidectin and sarolaner on heartworm disease dynamics was investigated in dogs. A compartmental model was developed to investigate different epidemiological settings considering different values for prevalence and host preference.
resultsWhen the mosquito host preference to dogs is low, a treatment compliance of only 40% decreases the proportion of infectious dogs. When the host preference of the mosquitoes however increases, an exponential increase in infectious dogs was observed, and a higher treatment compliance is required. In high transmission environments, with a high prevalence and a high mosquito host preference, a high treatment compliance (up to 100%) is required to have an impact on the number of infected animals. Notably, in scenarios with higher host preference towards dogs, more mosquitoes are exposed to sarolaner through the blood meal, leading to higher mortality of these mosquitoes and resulting in fewer infected and infectious dogs.
conclusionsThe preventive efficacy, as measured by the number of non-infected dogs, increases with increasing treatment compliance, but the extent of the treatment effect differs with the epidemiological setting. Adding sarolaner to a heartworm prevention has a complimentary impact on mosquito survival and heartworm disease transmission, although this effect depends on the epidemiological settings, emphasizing the true complexity of disease dynamics of a vector-borne disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.